Sökresultat

30 October 2025 10:00 to 15:15 | Conference Research Data in Transition: Infrastructure and Support at Lund University - registration required. Lund University is currently strengthening its support for research data management through the new Research Data Office (RDO) and a university-wide network of data stewards at each faculty. This comes at a critical moment: funders and journals now require

https://www.compile.lu.se/calendar/lu-escience-hub-data-management-solutions-lund-university - 2025-10-23

29 January 2026 09:30 to 15:30 | Seminar AI in Public Sector – Citizen Perspective. Welcome to AI Lund's annual fika-to-fika about AI in the public sector! Here we focus on both research and policy with a focus on public sector issues. The theme for this year is the citizen perspective. Which means that we will explore thoughts about how we as citizens are affected by and can influence AI in the p

https://www.compile.lu.se/calendar/ai-public-sector-2026 - 2025-10-23

17 November 2025 13:00 to 15:00 | Workshop Creating a research network to foster woman's partcipation in technoscience. An online lecture and on-site seminar in the serie Girls Just Want To Have Sc(AI)ence.Topic: Reimagining the Politics of AI: Co-Creating Tools to Confront Gender-Related ViolenceWhen & where:  17 November  202513.00 - 14.00: Hybrid lecture on zoom and LUX:C121 lecture hall, LUX,

https://www.compile.lu.se/calendar/girls-scaience-5-reimagining-politics-ai-co-creating-tools-confront-gender-related-violence - 2025-10-23

28 January 2026 12:00 to 13:00 | Seminar Topic: Building on the Shoulders of Humans: Copyright and Creativity in the Age of AIWhen: 28 January at 12.00-13.00Where: Online - link by registrationSpeaker: Dr. Johan Axhamn, Associate Professor in Business Law at Lund University School of Economics and ManagementSpoken language: EnglishAbstractGenerative AI systems are trained on vast datasets that inc

https://www.compile.lu.se/calendar/ai-lund-lunch-seminar-building-shoulders-humans-copyright-and-creativity-age-ai - 2025-10-23

19 November 2025 12:00 to 13:00 | Seminar Ämne: AI i Sverige: Från EU-regler till nationell verklighet – Vad innebär SOU 2025:101 för oss?Talare: TBATalat språk: SvenskaInnehållSverige står inför en ny era av AI-reglering. Den statliga utredningen SOU 2025:101 har nyligen presenterat förslag på hur EU:s AI-förordning ska anpassas till svenska förhållanden. Med fokus på säker användning, effektiv k

https://www.compile.lu.se/calendar/ai-lund-lunch-seminarium-ai-i-sverige-fran-eu-regler-till-nationell-verklighet-vad-innebar-sou - 2025-10-23

19 November 2025 12:00 to 13:00 | Seminar Ämne: AI in Sweden: From EU rules to national reality – What does SOU 2025:101 mean for us?Speakers: TBASpoken language: SwedishAbstractSweden is facing a new era of AI regulation. The government inquiry SOU 2025:101 has recently presented proposals on how the EU's AI regulation should be adapted to Swedish conditions. With a focus on safe use, effective c

https://www.compile.lu.se/calendar/ai-lund-lunch-seminar-ai-sweden-eu-rules-national-reality-what-does-sou-2025101-mean-us - 2025-10-23

Compile web page and eSSENCE@LU Melvyn B. Davies, email: melvyn_b [dot] davies [at] math [dot] lu [dot] se (melvyn_b[dot]davies[at]math[dot]lu[dot]se)Magnus Ullner, email: magnus [dot] ullner [at] compchem [dot] lu [dot] se (magnus[dot]ullner[at]compchem[dot]lu[dot]se)Josefin Starkhammar, email: josefin [dot] starkhammar [at] bme [dot] lth [dot] se (josefin[dot]starkhammar[at]bme[dot]lth[dot]se) e

https://www.compile.lu.se/contact - 2025-10-23

https://www.compile.lu.se/calendar/past-presentations - 2025-10-23

Welcome to CREATE Health Our vision: To contribute with innovative diagnostics and therapeutic solutions not for coming generations but for today's CREATE Health aims to provide individualized and improved therapeutic strategies, based on our ability to determine which patient will benefit from a particular treatment. CREATE Health provides solutions to clinical problems by developing innovative d

https://www.createhealth.lth.se/start - 2025-10-23

Centre Management Sara EkCenter Director, Director CanFastersara [dot] ek [at] immun [dot] lth [dot] se (sara[dot]ek[at]immun[dot]lth[dot]se) Corinna RichterResearch Coordinatorcorinna [dot] richter [at] immun [dot] lth [dot] se (corinna[dot]richter[at]immun[dot]lth[dot]se) Board Carl BorrebaeckChairman of the Boardcarl [dot] borrebaeck [at] immun [dot] lth [dot] se (carl[dot]borrebaeck[at]immun[d

https://www.createhealth.lth.se/about/centre-management-and-board - 2025-10-23

Open positions will be advertised on Lund University's website and on our social media channels.If you are a student and interested in doing a Master's or ExJobb project, please contact the PI of the group of interest directly.

https://www.createhealth.lth.se/about/recruitment - 2025-10-23

 Please wait...

https://www.createhealth.lth.se/about/principle-investigators - 2025-10-23

Links will open on the respective websites.Region SkåneMedicon VillageCHUV in LausanneTMUCI in Tianjin, ChinaOslo Cancer ClusterWorking together is an integral part of CREATE Health’s DNA. We can proudly say that CREATE Health’s researchers are highly engaged in many different collaborations and networks – too many to name all of them here. For detailed information on our researchers’ collaborativ

https://www.createhealth.lth.se/research-and-innovation/ongoing-collaborations-and-partners - 2025-10-23

CantargiaCantargia AB was founded in 2009/2010 by Thoas Fioretos and Marcus Järås (Lund University), Kjell Sjöström (Innovagen), and by LU Bioscience. The company specializes in antibody-based cancer therapy. After initially focusing on treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC), new antibodies designed for the treatment of autoimmune and inflammatory diseases hav

https://www.createhealth.lth.se/research-and-innovation/spin-outs - 2025-10-23

The Translational Cancer Faster Forward doctoral/postdoctoral programmes (2018-2025). The CanFaster programme is supported by the European Union’s Marie Skłodowska-Curie COFUND programme (Horizon 2020 framework) based on the "Mobility across borders" philosophy. The CanFaster programme has attracted international PhD and Postdoc fellows (ER) with an interest in applied medical research in oncology

https://www.createhealth.lth.se/canfaster - 2025-10-23

The links below open on the respective publication website.In vivo dendritic cell reprogramming for cancer immunotherapy.Authors: Ascic, E., Catena, X., et al.Publication: Science 386, 6719Year: 2024Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab.Authors: Meng, P., Dalal, H., Chen, Y., Brueffer, C., Gladchuk, S., Alcaide, M., ... &

https://www.createhealth.lth.se/canfaster/publications - 2025-10-23

Inducing anti-tumor immunity with in-situ direct reprograming of cancer cells to cDC1sNext generation immuno-oncological targets for cancer therapySubtype-dependent biomarkers for systemic therapy in bladder cancer

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects - 2025-10-23

Immunotherapy has transformed the cancer treatment landscape leading to long-term responses. However, these strategies are effective in a limited number of patients and often lose their efficacy as the tumor progresses. Insufficient antigen presentation mediated by MHC downregulation and exclusion of functional antigen-presenting cells (APCs) from the tumor microenvironment (TME) are critical evas

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/inducing-anti-tumor-immunity-situ-direct-reprograming-cancer-cells-cdc1s - 2025-10-23

Immuno-oncological (I-O) treatment methods have revolutionized cancer therapy and tremendous clinical benefits are achieved in some cancer patients. However, today a limited number of I-O drug targets are used and only a fraction of all cancer patients has a therapeutic response. We need to further understand the immune system in cancer in order to develop novel treatment strategies and improve su

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/next-generation-immuno-oncological-targets-cancer-therapy - 2025-10-23

Cancer in the urinary bladder afflicts around 3000 persons per year in Sweden, most often older men and smokers. Despite being a quite common cancer type it is an understudied cancer type considering the burden to society and health outcomes [1].To patients with superficial cancer limited to the mucosa of the urinary bladder, the prognosis is good, but once the tumor has grown into the muscle-laye

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/subtype-dependent-biomarkers-systemic-therapy-bladder-cancer - 2025-10-23